Developer of Russian coronavirus vaccine Betuvax company, part of HSCI, completed Phase I-II clinical trials, which confirmed the efficacy and safety of the drug. Vaccine was tested at three clinical centers in St. Petersburg and Perm with the participation of 116 volunteers who had not previously had covid and had not been vaccinated.